The National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has issued draft guidance recommending Skilarence (dimethyl fumarate).
Developed by Spanish drugmaker Almirall (ALM: MC), the drug looks set to be made available on the National Health Service as a treatment for moderate to severe plaque psoriasis.
Dimethyl fumarate is recommended for adults who have not responded to, or cannot take, other systemic non-biological treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze